CRISPR Therapeutics AG (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, announced on October 18, 2016 the pricing of its initial public offering of 4'000'000 common shares at a public offering price of $14.00 per share. CRISPR Therapeutics’ common shares have started trading on the NASDAQ Global Market under the ticker symbol "CRSP" on October 19, 2016. Citigroup, Piper Jaffray and Barclays acted as joint book-running managers for the offering. Guggenheim Securities acted as co-manager. In addition to the shares sold in the public offering, CRISPR Therapeutics also completed the concurrent sale of an additional 2'500'000 shares at the initial offering price of $14.00, for gross proceeds of $35.0 million, in a private placement to Bayer Global Investments B.V., an existing shareholder and an affiliate of Bayer HealthCare LLC, a joint venture partner with CRISPR Therapeutics. VISCHER AG and Goodwin Procter LLP are legal advisors to the Company.
The team at VISCHER is led by Matthias Staehelin (Partner Corporate) with Stefan Grieder (Partner Corporate), Nadia Tarolli (Partner Tax), Angelo Imperiale, Gian Caprez, Vincent Reardon and Luzius Zumstein (all Associates).